Table 2.
IPTW-weighted one-year costs after treatment initiation in patients treated with pirfenidone or nintedanib and related cost differences with bootstrapped 95% confidence intervals
| Pirfenidone (N = 840) | Nintedanib (N = 713) | ||
|---|---|---|---|
| Costs (in €) | Costs (in €) | Difference (in €) | |
| Overall | |||
| Total | 33,893 (32,559; 35,251) | 34,700 (33,407; 36,636) | − 807 (− 2977; 1220) |
| Inpatient | 5991 (5247; 7125) | 5590 (4739; 7376) | 400 (− 1130; 1849) |
| Outpatient | 1107 (1065; 1160) | 1271 (1187; 1410) | − 164 (− 280; − 55) |
| Pharmaceuticals | 26,796 (25,706; 28,008) | 27,839 (26,626; 28,880) | − 1043 (− 2638; 476) |
| Respiratory-related | |||
| Total | 29,085 (27,826; 30,344) | 30,366 (29,245; 32,082) | − 1282 (− 3423; 534) |
| Inpatient | 2867 (2369; 3717) | 3,096 (2398; 5163) | − 229 (− 1661; 884) |
| Outpatient | 690 (666; 717) | 693 (666; 726) | − 3 (− 42; 37) |
| Pharmaceuticals | 25,528 (24,416; 26,587) | 26,578 (25,443; 27,710) | − 1050 (− 2549; 473) |
Statistically significant results are marked in bold
Bootstrapping with 1000 repetitions, bias-corrected and accelerated bootstrap method